Business Context and Reporting Period
Artelo Biosciences, Inc. (Nasdaq: ARTL) filed a Current Report on Form 8-K dated October 28, 2025. The filing reports the entry into a Material Definitive Agreement involving a private placement of convertible notes and warrants.
Key Financial Metrics and Transaction Details
- Transaction Type: Issuance of convertible notes and warrants via a Subscription Agreement.
- Principal Amount: $690,154.69 in aggregate principal notes.
- Warrants Issued: 438,182 warrants to purchase common stock.
- Interest Rate: 12% per annum, adjustable to 20% upon an Event of Default.
- Maturity: Six months from the closing date (October 28, 2025).
- Conversion/Exercise Price: $3.40 per share for both notes and warrants.
- Warrant Term: 5 years, immediately exercisable.
- Ownership Limit: Conversion/exercise capped at 4.9% of outstanding shares (increasable to 19.9% at holder's election).
Material Changes and Related Party Transactions
The transaction involved the conversion of unpaid principal and accrued interest from convertible promissory notes issued on May 1, 2025, into new notes and warrants. Certain directors and officers participated in the offering, purchasing the following amounts:
| Name | Affiliation | Note Principal | Warrant Shares |
|---|---|---|---|
| Connie Matsui | Director | $110,842.52 | 70,376 |
| Tamara Favorito | Director | $19,792.93 | 12,566 |
| Gregory Gorgas | Director and Officer | $27,710.36 | 17,592 |
These related party transactions were disclosed to and approved by the board and disinterested board members.
Guidance, Outlook, and Obligations
- Registration Obligation: The Company agreed to file a registration statement within 20 calendar days of the closing date to register the resale of shares issuable upon conversion or exercise.
- Exemptions: The initial issuance relies on exemptions under Section 3(a)(9), Section 4(a)(2) of the Securities Act, and/or Rule 506 of Regulation D.
- Financial Impact: The filing does not provide updated revenue, profit, cash flow, or liquidity metrics. It focuses solely on the capital structure change.
Investor Verification Checklist
- Verify the Company's ability to file the required registration statement within the 20-day deadline.
- Review the full text of the Subscription Agreement (Exhibit 10.1) for specific default triggers and anti-dilution provisions.
- Assess the dilution impact of the 438,182 warrants and potential note conversions at the $3.40 price point.
- Confirm the status of the May 1, 2025 notes that were converted into this new offering.
- Monitor the Company's cash position given the 12% interest obligation and the six-month maturity horizon.